CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today reported operating results for the third quarter ended September 30, 2022, and provided a business update. Business Updates On ...

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the fourth quarter and full year ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the ...

Good afternoon, ladies and gentlemen. Thank you for attending today’s Bio-Rad Fourth Quarter and Full Year 2022 Earnings Results Conference Call. My name is Tia [ph], and I will be your moderator for ...

Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we ...

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...

Forbes contributors publish independent expert analyses and insights. I write about how manufacturing can serve and sustain a healthy Earth. Bio-based technology and manufacturing offer many ...

BioMarin BMRN reported 2022 financial results that were in line with our expectations, with roughly $2.1 billion in revenue (14% growth) and what we see as a maintainable turn to GAAP profitability.

The success of new year’s resolutions for 2023 won’t be known for months to come, but from the vantage point of December, it is easy to see that many large med-tech companies resolved to shed excess ...